Takeda Unit, U.S. Pharma See Mixed Results From IBD Drug Trials
This article was originally published in PharmAsia News
Takeda Pharmaceutical's U.S. unit and Sucampo Pharmaceuticals report mixed results from a pair of Phase III studies on Sucampo's Amitiza (lubiprostone) to treat opioid-induced bowel dysfunction. One trial met goals; the other fell short. Amitiza has U.S. clearance to treat chronic idiopathic constipation, but the trials for the other indication indicated the companies need to continue a separate study not expected to yield data until later this year. If that study is successful, the drug makers expect to apply to the U.S. FDA for approval next year. (Click here for more
You may also be interested in...
As generalist investors continue to push higher the stock prices of biotech companies that announce the most tenuous of coronavirus developments, the track record of biotech companies developing even vaccines for which the antigen is proven to be safe and efficacious remains poor.
In a bipartisan move, the US Senate is moving to impose new rules on companies - including those from China - seeking US initial public offerings, adding further uncertainty over such plans and further stoking trade tensions.
First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.